EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients

Weili Xiong, Ting Xu iD, Xiao Liu, Lili Zhang, Yuan Yuan iD

Cancer · 15.04.2024 · 130 (S8) · 1488-1498

DOI: 10.1002/cncr.35206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 25.01.2024. Verfasst von Weili Xiong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Neutropenia, Nanoparticles, Bridged-Ring Compounds. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Talents Program of Jiangsu Cancer Hospital, Jiangsu Provincial Medical Youth Talent, Jiangsu Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Taxanes are the basic components of breast cancer chemotherapy. Nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) shows improved antitumor effects because of more targeted delivery. However, the effects of nab‐paclitaxel have not been systematically studied in patients with metastatic breast cancer (MBC) pretreated with taxanes. Considering the limited treatment options for MBC, this study retrospectively evaluated the clinical efficacy and adverse effects of nab‐paclitaxel in patients with taxane‐pretreated MBC.

Methods

Patients who had previously received taxanes and subsequently received nab‐paclitaxel chemotherapy for MBC at Jiangsu Cancer Hospital between October 2014 and April 2022 were included for analysis. The primary end point was progression‐free survival (PFS), and the secondary end points were the objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), and side effects.

Results

A total of 236 female patients with MBC were included. The median PFS was 7.20 months (95% confidence interval [CI], 6.63–7.80 months), and the ORR, DCR, and CBR were 29.55% (95% CI, 23.50%–35.60%), 83.64% (95% CI, 78.70%–88.60%), and 56.36% (95% CI, 49.80%–63.00%), respectively. Following nab‐paclitaxel treatment, the median PFS of patients who were sensitive to taxanes during previous treatments was significantly longer than that of patients who were resistant to taxanes (7.57 months vs. 4.43 months, p < .001). The most common adverse events were sensory neuropathy (89.83%), neutropenia (48.73%), leukopenia (46.61%), and anemia (35.59%).

Conclusion

Nab‐paclitaxel demonstrated clinical activity in taxane‐pretreated patients with MBC. This beneficial effect was observed both in patients who were sensitive and resistant to taxanes during previous treatments. These results suggest nab‐paclitaxel as the preferred chemotherapy regimen in patients with MBC, regardless of their sensitivity to taxanes during previous treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeutropeniaNanoparticlesBridged-Ring CompoundsHumansFemaleAlbumin-Bound PaclitaxelRetrospective StudiesPaclitaxelTaxoidsAlbuminsAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

metastatic breast cancernab‐paclitaxeltaxane‐pretreatedtaxane‐resistanttaxane‐sensitive

Substanzen

130-nm albumin-bound paclitaxeltaxaneAlbumin-Bound PaclitaxelPaclitaxelTaxoidsAlbuminsBridged-Ring Compounds

Autor:innen und Institutionen

  • Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Chemotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.

ORCID-Profile: Ting Xu, Yuan Yuan

Förderung

  • Talents Program of Jiangsu Cancer Hospital
  • Jiangsu Provincial Medical Youth Talent
  • Jiangsu Cancer Hospital

Zitieren

APA

Xiong, W., Xu, T., Liu, X., Zhang, L., & Yuan, Y. (2024). Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients. Cancer, 130(S8), 1488-1498. https://doi.org/10.1002/cncr.35206

Vancouver

Xiong W, Xu T, Liu X, Zhang L, Yuan Y. Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients. Cancer. 2024;130(S8):1488-1498. doi:10.1002/cncr.35206

BibTeX
@article{Xiong2024,
  author = {Xiong, Weili and Xu, Ting and Liu, Xiao and Zhang, Lili and Yuan, Yuan},
  title = {Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {S8},
  pages = {1488--1498},
  doi = {10.1002/cncr.35206}
}
Kostenlos starten →